Skip to main content
Midas Edge

Atara Biotherapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 12, 2024

ATRA$8.10-1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

(In thousands)

Accumulated
Common · Additional · Other · Total
Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
For the Six Months Ended June 30, 2024SharesAmountCapitalIncome (Loss)DeficitEquity (Deficit)
Balance as of January 1, 20244,258$—$1,870,123$(204)$(1,969,150)$(99,231)
Issuance of pre-funded warrants to purchase common stock through a registered direct offering, net of offering costs of $177——$14,823——14,823
Issuance of common stock through ATM facilities, net of commissions and offering costs of $168493—9,312——9,312
RSU settlements, net of shares withheld63—(6)——(6)
Stock-based compensation expense——8,397——8,397
Net (loss) income————(31,752)(31,752)
Unrealized gain (loss) on available-for-sale securities———149—149
Balance as of March 31, 20244,814$—$1,902,649$(55)$(2,000,902)$(98,308)
RSU settlements, net of shares withheld81—(1)——(1)
Issuance of common stock pursuant to employee stock awards9—113——113
Stock-based compensation expense——6,336——6,336
Net (loss) income————(19,049)(19,049)
Unrealized gain (loss) on available-for-sale securities———41—41
Balance as of June 30, 20244,904$—$1,909,097$(14)$(2,019,951)$(110,868)
Accumulated
Common · Additional · Other · Total
Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
For the Six Months Ended June 30, 2023 · Shares · Amount · Capital · Income (Loss) · Deficit · Equity (Deficit)
Balance as of January 1, 20233,837$—$1,821,731$(2,067)$(1,693,024)$126,640
Issuance of common stock through ATM facilities, net of commissions and offering costs of $976—590——590
RSU settlements, net of shares withheld19—(93)——(93)
Stock-based compensation expense——11,764——11,764
Net (loss) income————(74,771)(74,771)
Unrealized gain (loss) on available-for-sale securities———830—830
Balance as of March 31, 20233,862$—$1,833,992$(1,237)$(1,767,795)$64,960
Exercise of pre-funded warrants116—————
RSU settlements, net of shares withheld43—(1)——(1)
Issuance of common stock pursuant to employee stock awards23—747——747
Stock-based compensation expense——12,552——12,552
Net (loss) income————(71,108)(71,108)
Unrealized gain (loss) on available-for-sale securities———304—304
Balance as of June 30, 20234,044$-$1,847,290$(933)$(1,838,903)$7,454
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.